Advanced Biotherapy Inc reported the results of a 30-patient randomised, double blind, placebo-controlled clinical trial evaluating the efficacy of its proprietary Anti-Interferon gamma drug (Anti-IFNg) in Rheumatoid Arthritis patients.

The Anti-IFNg-treated patients showed statistically significant improvements at both seven and 28 days post-treatment relative to placebo-treated patients in a variety of clinically relevant endpoints.

The clinical trial assessed the efficacy of a five-day intramuscular-administered (twice daily) treatment course of Anti-IFNg with that of placebo and Anti-Tumor Necrosis Factor alpha (Anti-TNFa).

The patients were clinically assessed for seven days on a daily basis and then weekly up to 28 days. The clinical parameters included numbers of swollen and painful joints, duration of morning stiffness, grip strength, pain and fatigue and both patient and physician global assessment. Both the Anti-Cytokine groups showed significant improvements at seven and 28 days with the Anti-IFNg group demonstrating the more robust effect at day 28.

Commenting on the results, Dr. Paul J. Marangos, chairman and CEO of ADVB, stated, "We are pleased that this second trial supports the results of our earlier published study in Rheumatoid Arthritis patients, and are excited about developing the Anti-IFNg treatment strategy into a marketable product."